Fabrice Egros's most recent trade in Syndax Pharmaceuticals Inc was a trade of 16,000 Common Stock done . Disclosure was reported to the exchange on Feb. 2, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Syndax Pharmaceuticals Inc | Fabrice Egros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2022 | 16,000 | 32,000 (0%) | 0% | 0 | Common Stock | |
| Syndax Pharmaceuticals Inc | Fabrice Egros | Director | Sale of securities on an exchange or to another person at price $ 18.03 per share. | 18 Nov 2021 | 14,000 | 16,000 (0%) | 0% | 18.0 | 252,452 | Common Stock |
| Syndax Pharmaceuticals Inc | Fabrice Egros | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.93 per share. | 18 Nov 2021 | 14,000 | 30,000 (0%) | 0% | 8.9 | 125,020 | Common Stock |
| Syndax Pharmaceuticals Inc | Fabrice Egros | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2021 | 14,000 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Fabrice Egros | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2021 | 30 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Fabrice Egros | Director | Sale of securities on an exchange or to another person at price $ 18.03 per share. | 18 Nov 2021 | 30 | 16,000 (0%) | 0% | 18.0 | 541 | Common Stock |
| Syndax Pharmaceuticals Inc | Fabrice Egros | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.87 per share. | 18 Nov 2021 | 30 | 16,030 (0%) | 0% | 7.9 | 236 | Common Stock |
| Syndax Pharmaceuticals Inc | Fabrice Egros | Director | Sale of securities on an exchange or to another person at price $ 15.75 per share. | 18 Aug 2021 | 15,635 | 16,000 (0%) | 0% | 15.8 | 246,328 | Common Stock |
| Syndax Pharmaceuticals Inc | Fabrice Egros | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2021 | 15,635 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Fabrice Egros | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.88 per share. | 18 Aug 2021 | 15,635 | 31,635 (0%) | 0% | 7.9 | 123,204 | Common Stock |
| Syndax Pharmaceuticals Inc | Fabrice Egros | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2021 | 11,926 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Fabrice Egros | Director | Sale of securities on an exchange or to another person at price $ 18.65 per share. | 18 May 2021 | 11,926 | 17,683 (0%) | 0% | 18.6 | 222,398 | Common Stock |
| Syndax Pharmaceuticals Inc | Fabrice Egros | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 18 May 2021 | 11,926 | 27,926 (0%) | 0% | 7.2 | 85,867 | Common Stock |
| Syndax Pharmaceuticals Inc | Fabrice Egros | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.88 per share. | 18 May 2021 | 1,683 | 29,609 (0%) | 0% | 7.9 | 13,262 | Common Stock |
| Syndax Pharmaceuticals Inc | Fabrice Egros | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2021 | 1,683 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Fabrice Egros | Director | Sale of securities on an exchange or to another person at price $ 18.65 per share. | 18 May 2021 | 1,683 | 16,000 (0%) | 0% | 18.6 | 31,385 | Common Stock |
| Syndax Pharmaceuticals Inc | Fabrice Egros | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 10,167 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Fabrice Egros | Director | Sale of securities on an exchange or to another person at price $ 24.31 per share. | 01 Mar 2021 | 10,167 | 16,074 (0%) | 0% | 24.3 | 247,182 | Common Stock |
| Syndax Pharmaceuticals Inc | Fabrice Egros | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.35 per share. | 01 Mar 2021 | 10,167 | 26,167 (0%) | 0% | 6.3 | 64,560 | Common Stock |
| Syndax Pharmaceuticals Inc | Fabrice Egros | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 74 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Fabrice Egros | Director | Sale of securities on an exchange or to another person at price $ 24.31 per share. | 01 Mar 2021 | 74 | 16,000 (0%) | 0% | 24.3 | 1,799 | Common Stock |
| Syndax Pharmaceuticals Inc | Fabrice Egros | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 01 Mar 2021 | 74 | 26,241 (0%) | 0% | 7.2 | 533 | Common Stock |
| Syndax Pharmaceuticals Inc | Fabrice Egros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 16,000 | 16,000 (0%) | 0% | 0 | Common Stock |